Sand Grove Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sand Grove Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-224,632	Closed	-$13.2M	–	30
2023 Q4	$13.2M	Buy	+224,632	New	+$12.6M	3.51%	11

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sand Grove Capital Management's MRTX Position: Q1 2024 in Review

Sand Grove Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 224,632 shares — an estimated $13.2M sold.

Sand Grove Capital Management first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $13.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Sand Grove Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Sand Grove Capital Management sold 224,632 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.2M.
Sand Grove Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Sand Grove Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13.2M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Sand Grove Capital Management's 13F filing for Q1 2024, filed 14 May 2024.